Kiwi, well said. I agree. A win is first and foremost. Scripts may be affected by the current virus situation and market disruptions that are outside of JT’s control. It most likely will affect scripts and other growth metrics but AMRN can’t do much about that and they won’t be the only ones impacted. All AMRN can do is continue to execute the launch and continue educating/negotiating with formularies, pharmacies, and potential suitors as well as fine tune advertising and messaging. Got to get past judges decision first and we can worry about the rest later. After that, AMRN will either be bought or they’ll hit the advertising and educational blitz hard in Q2. IMO